A clinical trial study to determine the prevention reduction of stretch marks and relief of itchy skin in antenatal women

An open-label randomized multi-center multi-dose two treatment parallel-group study to determine the safety and effiicacy of Jojo E Cream and Jojo E Serum in the prevention and reduction for stretch marks and relief of dry and Itchy skin compared to healthy controls in antenatal women

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/07/034674

Enrollment

Registered

2021-07-07

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: O94-O9A- Other obstetric conditions, not elsewhere classified

Interventions

Intervention1: Jojo cream : 7-8 gram daily (for 6months) Topical application Helps in the reduction of stretch marks and dry and relief of and itchy skin Intervention2: Jojo E serum : 10-12 drops d

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age between 18-30 years at recruitment. 2. Primigravida women. 3. Multigravida women or with already existing striae from earlier weight loss or any other reasons. 4. Singleton/Multiple pregnancies. 5. Pregnant women between 12–14 weeks of gestation 40% with mild abdominal striae and 60% with absence of abdominal striae 6. Voluntarily participating in the clinical study; fully understanding and being fully informed of the study and has signed the Informed Consent Form (ICF); willingness and capability to complete all the study procedures.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Proportion of Antenatal women with absence of Striae Gravidarum at Post-delivery (30 days +/- 5 days after delivery) between the treatment groups. Proportion of Antenatal women with mild, moderate and severe striae at Post-delivery (30 days +/- 5 days after delivery) between the treatment groupsTimepoint: Week 16, Week 26, Week 36, Post delivery	—

Secondary

Measure	Time frame
ensure the primary outcome at specified time pointsTimepoint: Week 16, Week 26, Week 36, post delivery	—

Countries

India

Contacts

Public ContactDr R Senthurselvi

MBBS MD

senthurselvi.r@spinoslifescience.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026